PPARA and metabolic dysfunction-associated steatohepatitis: Nevertheless, these agents could be tested in a more efficient way when interspecies differences regarding (i) the PPAR biology, (ii) responses to PPAR agonism, and (iii) specific polymorphisms related to NASH pathology could be taken out of the equation.